Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Privately-held Dutch biotech Amarna Therapeutics has appointed Dr Henk Streefkerk as the company’s new chief executive and medical director. 7 June 2023
Flagship Pioneering founded company Ring Therapeutics today announced the appointment of Konstantin Konstantinov as its chief technology officer. 7 June 2023
Swiss biotech Idorsia today revealed that Simon Jose will leave his position as chief commercial officer and member of the Idorsia executive committee to pursue other opportunities. 30 May 2023
UK-based Senisca, a biotech company developing RNA-based therapeutics to reverse cellular senescence and target age-related disease, has announced an expansion of its leadership team. 18 May 2023
Gilead Sciences has announced that Cindy Perettie will join the firm as executive vice president of its subsidiary company Kite, overseeing the cell therapy business. 17 May 2023
Pan Cancer T, a spin-off from The Netherlands’ Erasmus Medical Center focused on the discovery and development of next-generation TCR-T therapies against solid tumors, has a new boss. 12 May 2023
UK-based cancer immunotherapy company Immodulon has named Richard Davies its new chairman of the board, appointed Gertjan Bartlema chief executive and brought in Peter Greaney as chief business officer. 10 May 2023
Cambridge, USA-based Orbital Therapeutics, which debuted last September with the vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible, has now announced the successful closing of a $270 million Series A financing. 27 April 2023
UK-based company Epsilogen is even more confident in its claim to be a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer following three new senior hires. 26 April 2023
USA-based company ImmunoGen, a specialist in the field of antibody-drug conjugates (ADCs) for the treatment of cancer, has appointed Isabel Kalofonos as senior vice president and chief commercial officer. 24 April 2023
Danish clinical-stage retinal diseases biotech Breye Therapeutics today announced the appointment of Peter Adamson as chief scientific Officer (CSO). 20 April 2023